Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + PDT vs ranibizumab + PDT vs pegaptanib + PDT in neovascular age-related macular degeneration
2009-013062-11Phase 3Active
- Sponsor
- Azienda USL 8 Arezzo
- Start
- Jun 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, ranibizumab, pegaptanib sodium and verteporfin in exudative macular degeneration and age-related macular degeneration (AMD) (3 arms), sponsored by Azienda USL 8 Arezzo. Primary endpoint: Visual acuity loss at 12 months. Started Jun 2009; status: active.
02
Drugs
bevacizumabranibizumabpegaptanib sodiumverteporfin
03
Conditions
exudative macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2009-013062-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013062-11.